Related content

A Cost-Effectiveness Analysis of Docetaxel in the Second-Line Treatment of Non-Small Cell Lung Cancer

By Holmes J.  

PharmacoEconomics, Vol. 22, Iss. 9, 2004-01 ,pp. : 581-589

Adis International

Access to resources Recommend Favorite

Cost-effectiveness of Erlotinib versus Docetaxel for Second-line Treatment of Advanced Non-small-cell Lung Cancer in the United Kingdom

By Lewis G   Peake M   Aultman R   Gyldmark M   Morlotti L   Creeden J   de la Orden M  

The Journal of International Medical Research, Vol. 38, Iss. 1, 2010-01 ,pp. : 9-21

Field House Publishing

Access to resources Recommend Favorite

Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine

By Sasaki Takashi  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 708-713

Springer Publishing Company

Access to resources Recommend Favorite

ABCB1, SLCO1B1 and UGT1A1 Gene Polymorphisms Are Associated with Toxicity Line Irinotecan

By  

Drug Metabolism Letters, Vol. 1, Iss. 1, 2007-01 ,pp. : 23-30

Bentham Science Publishers

Access to resources Recommend Favorite

Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer

By Hoff Paulo   Saad Everardo   Pazdur Richard   Wolff Robert   Lassere Yvonne   Bogaard Karla   Abbruzzese James  

Investigational New Drugs, Vol. 22, Iss. 3, 2004-08 ,pp. : 307-313

Springer Publishing Company

Access to resources Recommend Favorite